Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study.

Published

Journal Article

OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is an iatrogenic fibrosing disorder that primarily affects individuals with chronic kidney disease (CKD) following exposure to gadolinium-based contrast agents (GBCAs). Derangements of calcium and phosphorus have been reported in patients with NSF. The aim of this study was to investigate potential factors in addition to GBCA exposure that may be involved in the pathogenesis of NSF. We hypothesized that patients with stage 5 CKD and NSF would manifest greater alterations in calcium, phosphorus and fibroblast growth factor 23 (FGF23) levels than those who do not have NSF. METHODS: Levels of phosphorus, calcium, FGF23 and 25-hydroxy-vitamin D were measured in 10 patients with stage 5 CKD and biopsy-proven NSF and in 19 patients with stage 5 CKD without NSF. Statistical analyses were performed using Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables. RESULTS: Patients with NSF had significantly lower phosphorus levels compared with controls (P = 0.01). There were no significant differences between NSF patients and controls in calcium, 25-hydroxy-vitamin D, intact parathyroid hormone or FGF23 levels. CONCLUSION: Differences in phosphorus metabolism may exist between patients with stage 5 CKD and NSF compared with patients with stage 5 CKD without NSF.

Full Text

Duke Authors

Cited Authors

  • Bernstein, EJ; Isakova, T; Sullivan, ME; Chibnik, LB; Wolf, M; Kay, J

Published Date

  • September 2014

Published In

Volume / Issue

  • 53 / 9

Start / End Page

  • 1613 - 1617

PubMed ID

  • 24706993

Pubmed Central ID

  • 24706993

Electronic International Standard Serial Number (EISSN)

  • 1462-0332

Digital Object Identifier (DOI)

  • 10.1093/rheumatology/keu151

Language

  • eng

Conference Location

  • England